WO2000047563A1 - LACTAM INHIBITORS OF FXa AND METHOD - Google Patents
LACTAM INHIBITORS OF FXa AND METHOD Download PDFInfo
- Publication number
- WO2000047563A1 WO2000047563A1 PCT/US2000/001859 US0001859W WO0047563A1 WO 2000047563 A1 WO2000047563 A1 WO 2000047563A1 US 0001859 W US0001859 W US 0001859W WO 0047563 A1 WO0047563 A1 WO 0047563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chiral chiral
- compound
- alkyl
- cycloheteroalkyl
- heteroaryl
- Prior art date
Links
- 0 C1CO*CNC1 Chemical compound C1CO*CNC1 0.000 description 3
- DNAHSKQYMCWRNL-LTSZJICASA-N B[C@](CCCCN1CC(C2C(CCCCC)C2)=O)(C1=O)NC(Nc1cc(Cl)cc(Cl)c1)=O Chemical compound B[C@](CCCCN1CC(C2C(CCCCC)C2)=O)(C1=O)NC(Nc1cc(Cl)cc(Cl)c1)=O DNAHSKQYMCWRNL-LTSZJICASA-N 0.000 description 1
- CNFZRHCYZLYPJY-UHFFFAOYSA-N Cc1cc(NC(NC(CCCCN2CC(N3CCCC3)=O)C2=O)=O)ccc1 Chemical compound Cc1cc(NC(NC(CCCCN2CC(N3CCCC3)=O)C2=O)=O)ccc1 CNFZRHCYZLYPJY-UHFFFAOYSA-N 0.000 description 1
- QMMUUOBRIJYXOE-UHFFFAOYSA-N O=C(CN(CCCCC1)C1=O)N1CCCC1 Chemical compound O=C(CN(CCCCC1)C1=O)N1CCCC1 QMMUUOBRIJYXOE-UHFFFAOYSA-N 0.000 description 1
- XLUGHNXUZBYLPL-UHFFFAOYSA-N O=C(CN(CCCCC1NC(NC(c2ccccc2)=O)=O)C1=O)N1CCCC1 Chemical compound O=C(CN(CCCCC1NC(NC(c2ccccc2)=O)=O)C1=O)N1CCCC1 XLUGHNXUZBYLPL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to lac arn inhibitors of the enzyme Factor Xa which are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses .
- novel substituted lactam derivatives which are inhibitors of the enzyme Factor Xa and have the structure I
- R 1 and R 2 are the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl , cycloalkyl, cycloalkylalkyl , polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, or R 1 and R 2 can be taken with the nitrogen to which they are attached to form a cycloheteroalkyl ring; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl
- X is R*—c or R 3— s
- R 3 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl , polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, or polycycloalkenylalkyl; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalken
- R 7 and R 8 are independently selected from alkyl, alkenyl , alkynyl , aryl , heteroaryl , arylalkyl , heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalky
- R 1 and R 2 are independently alkyl, cycloalkyl, alkenyl , phenyl , benzyl , cyanoalkyl , alkoxycarbonylalkyl , or phenyl mono- or disubstituted with lower alkyl, cyano, hydroxy, dialkylamino, alkoxy, benzyloxy, alkylamino, alkoxycarbonyl, pyrrolidino, morpholino, halogen, alkyl substituted with one or more fluorines, then Y is S; (2) where R 1 and R 2 are alkyl, then Y is S; and
- R 1 and R 2 are alkyl and Y is O, then the other is alkynyl, heteroaryl, heteroarylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl or R 1 and R 2 can be taken with the nitrogen to which they are attached to form a cycloheteroalkyl ring, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 substituents as defined for R 1 and R 2 .
- R 2 together with the nitrogen to which they are attached form a cycloheteroalkyl ring, preferably a pyrrolidinyl ring
- Y is S
- one of R 5 and R 6 is hydrogen and the other of R 5 and R 6 is aryl, alkylaryl or alkoxyaryl such as phenyl, 3-methylphenyl or 3-methoxyphenyl, 4-cyanophenyl, 3- fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4- methoxyphenyl , 3-chloro-4-methylphenyl , 3 , 5-dichlorophenyl, 3-iodophenyl, 3 , 5-dimethylphenyl or naphthyl .
- a method for preventing, inhibiting or treating cardovascular diseases associated with thromboses wherein a compound of formula I is administered in a therapeutically effective amount which inhibits Factor Xa.
- a compound of formula I is administered in a therapeutically effective amount which inhibits Factor Xa.
- alkyl or “alk” as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons (in the case of alkyl or alk), preferably 1 to 20 carbons, more preferably 1 to 12 carbons (in the case of lower alkyl) , in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t- butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4- dimethylpentyl , octyl, 2 , 2, 4-trimethylpentyi, nonyl, decyl, undecyl, dodecyl, the various additional branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents which may be any of the R 1 or the R 1 substituents set out herein.
- cycloalkyl as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to one aromatic ring as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
- cycloalkenyl as employed herein alone or as part of another group r3fers to cyclic hydrocarbons containing 5 to 20 carbons, preferably 6 to 12 carbons and 1 or 2 double bonds .
- exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.
- aryl refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, aryl
- aralkyl refers to alkyl groups as discussed above having an aryl substituent, such as benzyl or phenethyl, or naphthylpropyl , or an aryl as defined above.
- aryl substituent such as benzyl or phenethyl, or naphthylpropyl , or an aryl as defined above.
- lower alkoxy as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.
- amino as employed herein alone or as part of another group may optionally be independently substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl , alkoxyalkyl or thioalkyl .
- substituents may be further substituted with a carboxylic acid or any of the R 1 groups or R 1 substituents thereof as set out above.
- amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-l-piperazinyl, 4-arylalkyl-l-piperazinyl, 4-diarylalkyl-l-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.
- lower alkylthio alkylthio, alkylthio, arylthio, or “aralkylthio” as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.
- lower alkylamino as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.
- acyl refers to an organic radical linked to a carbonyl ( c " ; ) group; examples of acyl groups include any of _..e R 1 groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.
- alkanoyl as used herein alone or as part of another group refers to alkyl linked to a carbonyl group .
- lower alkenyl or “alkenyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to
- 1 to 8 carbons in the normal chain which include one to six double bonds in the normal chain, such as vinyl, 2- propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2- hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3- octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4, 8, 12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino , alkylamido, arylcarbonylamino
- lower alkynyl or “alkynyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably
- 2 to 8 carbons in the normal chain which include one triple bond in the normal chain, such as 2-propynyl, 3- butynyl , 2-butynyl , 4-pentyny1 , 3-pentyny1 , 2-hexynyl , 3- hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3- nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbon
- alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed “alkylene” groups and may optionally be substituted as defined above for “alkyl”.
- alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed “alkenylene groups” and “alkynylene groups”, respectively, and may optionally be substituted as defined above for “alkenyl” and “alkynyl”.
- Suitable alkylene, alkenylene or alkynylene groups (CH 2 ) p (where, p is 1 to 8, preferably 1 to 5) (which may include alkylene, alkenylene or alkynylene groups) as defined herein, may optionally include 1, 2, or 3 substituents which include any of the R 1 groups, or the R 1 substituents set out herein.
- alkylene, alkenylene and alkynylene include
- halogen or "halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF 3 , with chlorine or fluorine being preferred.
- metal ion refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.
- cycloheteroalkyl refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker (CH 2 ) P (which is defined above) , such as
- the above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of of the R 1 groups, or the R 1 substituents set out herein.
- any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.
- heteroaryl refers to a 5- or 6- membered aromatic ring which includes 1 , 2 , 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl) , and includes possible N-oxides .
- the heteroaryl group may optionally include 1 to 4 substituents such as any of the R 1 groups or the R 1 substituents set out above. Examples of heteroaryl groups include
- cycloheteroalkylalkyl refers to cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a (CH 2 ) p chain.
- heteroarylalkyl or “heteroarylalkenyl” as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to a -(CH 2 ) P - chain, alkylene or alkenylene as defined above.
- polyhaloalkyl refers to an "alkyl” group as defined above which includes from 2 to 9 , preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF 3 CH 2 , CF 3 or CF 3 CF 2 CH2.
- polyhaloalkyloxy refers to an "alkoxy” or “alkyloxy” group as defined above which includes from 2 to 9, preferably from 2 to 5 , halo substituents, such as F or Cl, preferably F, such as CF 3 CH 2 O, CF 3 O or CF 3 CF 2 CH 2 O.
- the compounds of formula I can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, ⁇ ---taric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine) , or benzoic acid, or with
- Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
- the compounds of formula I having at least one acid group can also form salts with bases.
- Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine .
- Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included. Preferred salts of the compounds of formula I include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.
- All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
- the compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents.
- compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof.
- the processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials.
- enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.
- the present invention includes prodrug forms of the compounds of formula I such as alkylesters of acids or any known prodrugs for lactam derivatives .
- the compounds of the instant invention may, for example, be in the free or hydrate form, and may be obtained by methods exemplified by the following descriptions .
- the compounds of formula I may be prepared by the exemplary processes described in the following reaction schemes . Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.
- an inert organic solvent such as dichloromethane, chloroform or tetrahydrofuran
- Compound 1 is a novel compound provided that R 1 and R 2 are as defined herein, but excludes alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or polycycloalkyl.
- R 5 X is R 4 c Y is O and R* is ⁇
- Procedure A For amines where R 1 and/or R 2 contain additional basic nitrogens.
- Procedure B For amines where R 1 and/or R 2 contain no additional basic nitrogens.
- Procedure A for amines where R 1 and/or R 2 contain additional basic nitrogens, a mixture of a solution of amine 21 in an inert organic solvent such as THF, methylenechloride or chloroform, a carbodiimide such as diisopropylcarbodiimide (DIC) and 7-aza-1-hydroxy- benzotriazole (HOAt) is reacted with acid 20., employing a molar ratio of amine 21 . : acid 20. within the range from about 5:1 to about 1:5, preferably at about 1:1.1, to form a reaction mixture which is purified via an SCX column to separate out compound IB of the invention.
- an inert organic solvent such as THF, methylenechloride or chloroform
- DIC diisopropylcarbodiimide
- HOAt 7-aza-1-hydroxy- benzotriazole
- the DIC will be employed in a molar ratio to acid 20. within the range from about 5:1 to about 1:5, preferably at about 1.6:1, and the HOAt will be employed in a molar ratio acid 20. within the range from about 5:1 to about 1:5, preferably at about 1.6:1.
- Procedure B for amines where R 1 and/or R 2 contain no additional basic nitrogens a mixture of a solution of amine 21 in an inert organic solvent such as THF , methylenechloride or chloroform, ethyldimethylaminopropylcarbodiimide (EDAC) and dimethylaminopyridine (D AP) with acid 20., employing a molar ratio of amine 21: acid 20 . within the range from about 5:1 to about 1:5, preferably at about 1.5:1, to form a reaction mixture which is purified via a SCX column to separate out compound IB of the invention.
- an inert organic solvent such as THF , methylenechloride or chloroform, ethyldimethylaminopropylcarbodiimide (EDAC) and dimethylaminopyridine (D AP)
- EDAC ethyldimethylaminopropylcarbodiimide
- D AP dimethylamino
- the EDAC will be employed in a molar ratio to acid 20 . within the range from about 5:1 to about 1.5, preferably at about 1.5:1, and the DMAP will be employed in a molar ratio to acid 20. within the range from about 5:1 to about 1:5, preferably at about 1.5:1.
- Starting compound 20 can be prepared by methods known in the art as outlined in Reaction Scheme IIA.
- X is R4— c- Y is 0 or S, and R 4 is N-
- amine 1 in an inerc organic solvent such as dichloromethane, chloroform or tetrahydrofuran
- reactant 30. or 3JL employing a molar ratio of 30 or 31 : amine 1 within the range of from about 5:1 to about 1:5, followed by treatment with aminomethylpolystyrene (.32) , affords the compound of the invention IB' or IB".
- the compounds of the present invention are inhibitors of the activated coagulation serine protease known as Factor Xa and thus are useful for the treatment or prophylaxis of those processes which involve the oroduction and/or action of Factor Xa.
- the compounds of the invention are useful in the treatment or prevention of thrombotic events associated with coronary artery and cerebrovascular disease.
- the compounds of the invention are also useful as inhibitors of blood coagulation such as during the preparation, storage and fractionation of whole blood.
- the present compounds may also be useful in maintaining whole and fractionated blood in the fluid phase such as required for analytical and biological testing.
- Examples include, but are not limited to, ex vivo platelet and other cell function studies, bioanalytical procedures and quantitation of blood-containing components.
- the compounds of the present invention may be useful to prevent restenosis following arterial injury induced by endogenous (rupture of an atherosclerotic plaque) or exogenous (invasive cardiological procedure such as vessel wall injury resulting from angioplasty) events.
- the compounds of the present invention may also be used as an anticoagulant in extracorpeal blood circuits, such as those necessary in dialysis and surgery (such as coronary artery bypass surgery) .
- the compounds of the present invention may be useful for maintaining blood vessel patency in conjunction with vascular surgery including bypass grafting, arterial reconstruction, atherectomy, vascular graft and stent patency, organ, tissue and cell implantation and transplantation.
- the compounds of the present invention may be useful for the treatment of heparin-intolerant patients, including those with congenital and acquired antithrc bin III deficiencies, heparin-induced thrombocytopenia, and those with high levels of polymorphonuclear granulocyte elastase.
- the compounds of the present invention may also be useful for the treatment of inflammatory diseases and the prevention of septic shock and vascular damage due to bacterial and/or Mral infections.
- the compounds of the present invention may also be useful in the treatment of malignancies, prevention of metastases, prevention of prothrombotic complications of cancer, and as an adjunct to chemotherapy.
- the compounds of the present invention may also be used in combination with prothrombolytic agents, such as tissue plasminogen activator (natural or recombinant) , streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC) , animal salivary gland plasminogen activators, and the like.
- prothrombolytic agents such as tissue plasminogen activator (natural or recombinant) , streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC) , animal salivary gland plasminogen activators, and the like.
- prothrombolytic agents such as tissue plasminogen activator (natural or recombinant) , strepto
- the compounds of the present invention may also inhibit other serine proteases, for example, thrombin, Factor Vila, urokinase-type plasminogen activator (urokinase) , tryptase and/or trypsin.
- these compounds may additionally be useful as angiogenesis inhibitors in the treatment of cancer, as antiinflammatory agents particularly in the treatment of chronic asthma and in the treatment or prevention of allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and conjunctivitis and in the treatment or prevention of pancreatitis.
- the compounds of the present invention may also be used in combination with other antithrombotic or anticoagulant drugs such as thrombin inhibitors , platelet aggregation inhibitors such as clopidogrel, ticlopidine, PAI-1 inhibitors such as XR-330 and T-686, inhibitors of ⁇ -2-antiplasmin such as anti- ⁇ -2-antiplasmin antibody and thromboxane receptor antagonists (such as ifetroban) , prostacyclin mimetics, phosphodiesterase (PDE) inhibitors, such as dipyridamole or cilostazol, PDE inhibitors in combination with thromboxane receptor antagonists/thromboxane A synthetase inhibitors (such as picotamide) , serotonin-2-receptor antagonists (such as ketanserin), fibrinogen receptor antagonists, aspirin, hypolipidemic agents, (such as HMG-CoA reductase inhibitors for example pravastatin or si vastatin, or
- Patent Nos . 5,739,135, 5,712,279 and 5,760,246) antihypertensive agents, (such as angiotensin converting enzyme inhibitors, for example, captopril, lisinopril or fosinopril, angiotensin II receptor antagonists, for example, irbesartan, losartan or valsartan, and ACE/NEP inhibitors, for example omapatrilat) , PDE inhibitors in combination with aspirin, ifetroban, picotamide, ketanserin or clopidogrel and the like.
- antihypertensive agents such as angiotensin converting enzyme inhibitors, for example, captopril, lisinopril or fosinopril, angiotensin II receptor antagonists, for example, irbesartan, losartan or valsartan, and ACE/NEP inhibitors, for example omapatrilat
- the compounds of the invention can be administered orally or parenterally such as subcutaneously or intravenously, as well as by nasal application, rectally or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses .
- the active substance can be utilized in a composition such as tablet, capsule, solution or suspension or in other type carrier materials such as transdermal devices, iontophoretic devices, rectal suppositories, inhalant devices and the like.
- the composition or carrier will contain about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formulas I, IA. , IB, IC and ID. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc. as called for by accepted pharmaceutical practice.
- the title compound was prepared as part of an automated solution phase run using a liquid handler (Hamilton Microlab ® 2200) for reagent and starting material addition using the following procedure.
- a liquid handler Halton Microlab ® 2200
- the product was purified via solid phase extraction using a Varian SCX cation exchange coluiri (1 g of sorbent in 6 mL column, 0.3 meq/g) by the procedure outlined below: 1) Column conditioned with 2 x 7.5 mL of MeOH (10 mL/min) .
- Example 5 was prepared as part of an automated solution phase run using a liquid handler (Hamilton
- the product was purified via solid phase extraction using a Varian SCX cation exchange column (1 g of sorbent in 6 mL column, 0.3 meq/g) by the procedure outlined below.
- Example 5 compound (94%) as an oil.
- Reverse phase analytical HPLC analysis indicated a purity of 97%.
- Part B compound (4.1 g, 12.1 mmol) in 100 mL of CH 2 C1 2 was added 100 mL of HCl in Et 2 0 (1.0 M) at room temperature. The mixture was stirred for 14h. The solvent was removed in vacuum and the resulting residue was purified by ion-exchange resin column chromatography (elute with 2% ammonia in MeOH) to yield title compound (1.91 g, 66.0%) as yellow oil. Found: MH + : 240.2.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000598484A JP2002536437A (en) | 1999-02-09 | 2000-01-27 | FXa lactam inhibitors and methods |
CA002361919A CA2361919A1 (en) | 1999-02-09 | 2000-01-27 | Lactam inhibitors of fxa and method |
AU26300/00A AU756174B2 (en) | 1999-02-09 | 2000-01-27 | Lactam inhibitors of FXa and method |
EP00904564A EP1175405A4 (en) | 1999-02-09 | 2000-01-27 | LACTAM INHIBITORS OF FXa AND METHOD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11937499P | 1999-02-09 | 1999-02-09 | |
US60/119,374 | 1999-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000047563A1 true WO2000047563A1 (en) | 2000-08-17 |
Family
ID=22384077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001859 WO2000047563A1 (en) | 1999-02-09 | 2000-01-27 | LACTAM INHIBITORS OF FXa AND METHOD |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1175405A4 (en) |
JP (1) | JP2002536437A (en) |
AU (1) | AU756174B2 (en) |
CA (1) | CA2361919A1 (en) |
WO (1) | WO2000047563A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079261A1 (en) * | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
WO2001096331A1 (en) * | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Lactam inhibitors of factor xa and method |
WO2002012196A2 (en) * | 2000-08-07 | 2002-02-14 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
WO2002100886A1 (en) * | 2001-06-08 | 2002-12-19 | Glaxo Group Limited | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
EP1307203A1 (en) * | 2000-03-21 | 2003-05-07 | Smithkline Beecham Corporation | Protease inhibitors |
WO2003043981A1 (en) * | 2001-11-16 | 2003-05-30 | Glaxo Group Limited | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors |
US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
EP1667647A2 (en) * | 2003-10-01 | 2006-06-14 | Bristol-Myers Squibb Company | Monocyclic and bicyclic lactams as factor xa inhibitors |
US7186717B2 (en) | 2001-06-08 | 2007-03-06 | Smithkline Beecham Corporation | Pyrrolidine derivatives as Factor Xa inhibitors |
EP2982668A2 (en) | 2002-12-03 | 2016-02-10 | Pharmacyclics LLC | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155102A (en) * | 1990-06-21 | 1992-10-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | 1-alkyl-3-(acylamino)-ε-caprolactames as enhancers of learning and memory and pharmaceutical compositions containing same |
WO1996011940A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Acyl amino acetamide derivatives with agonist activity for cck-a receptors |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10503176A (en) * | 1994-06-17 | 1998-03-24 | コーバス インターナショナル, インコーポレイテッド | 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors |
JP2001504810A (en) * | 1996-10-11 | 2001-04-10 | シーオーアール・セラピューティックス・インコーポレーテッド | Selective factor Xa inhibitor |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
-
2000
- 2000-01-27 CA CA002361919A patent/CA2361919A1/en not_active Abandoned
- 2000-01-27 WO PCT/US2000/001859 patent/WO2000047563A1/en not_active Application Discontinuation
- 2000-01-27 AU AU26300/00A patent/AU756174B2/en not_active Ceased
- 2000-01-27 EP EP00904564A patent/EP1175405A4/en not_active Withdrawn
- 2000-01-27 JP JP2000598484A patent/JP2002536437A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155102A (en) * | 1990-06-21 | 1992-10-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | 1-alkyl-3-(acylamino)-ε-caprolactames as enhancers of learning and memory and pharmaceutical compositions containing same |
WO1996011940A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Acyl amino acetamide derivatives with agonist activity for cck-a receptors |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
Non-Patent Citations (1)
Title |
---|
See also references of EP1175405A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7071184B2 (en) | 2000-03-21 | 2006-07-04 | Smithkline Beecham Corporation | Protease inhibitors |
EP1307203A4 (en) * | 2000-03-21 | 2005-08-17 | Smithkline Beecham Corp | Protease inhibitors |
EP1307203A1 (en) * | 2000-03-21 | 2003-05-07 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001079261A1 (en) * | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
US6544981B2 (en) | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
WO2001096331A1 (en) * | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Lactam inhibitors of factor xa and method |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
WO2002012196A2 (en) * | 2000-08-07 | 2002-02-14 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
WO2002012196A3 (en) * | 2000-08-07 | 2003-01-16 | Bristol Myers Squibb Co | Lactam compounds and their use as inhibitors of serine proteases and method |
US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
US7186717B2 (en) | 2001-06-08 | 2007-03-06 | Smithkline Beecham Corporation | Pyrrolidine derivatives as Factor Xa inhibitors |
US7429587B2 (en) | 2001-06-08 | 2008-09-30 | Glaxo Group Limited | Pyrrolidine derivatives as factor Xa inhibitors |
EP1839659A3 (en) * | 2001-06-08 | 2011-05-04 | Glaxo Group Limited | Chemicals compounds |
US7084139B2 (en) | 2001-06-08 | 2006-08-01 | Smithkline Beecham Corporation | Pyrrolidin-2-one derivatives as inhibitors of factor Xa |
US7517879B2 (en) | 2001-06-08 | 2009-04-14 | Glaxo Group Limited | Pyrrolidine derivatives as factor Xa inhibitors |
WO2002100886A1 (en) * | 2001-06-08 | 2002-12-19 | Glaxo Group Limited | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
US7226929B2 (en) | 2001-06-08 | 2007-06-05 | Smithkline Beecham Corporation | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
EP1839659A2 (en) * | 2001-06-08 | 2007-10-03 | Glaxo Group Limited | Chemicals compounds |
US7282497B2 (en) | 2001-06-08 | 2007-10-16 | Glaxo Group Limited | Pyrrolidin-2-one derivatives as inhibitors of factor xa |
US7326785B2 (en) | 2001-06-08 | 2008-02-05 | Glaxo Group Limited | Pyrrolidine derivatives as factor XA inhibitors |
US7179835B2 (en) | 2001-11-16 | 2007-02-20 | Glaxo Group Limited | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors |
WO2003043981A1 (en) * | 2001-11-16 | 2003-05-30 | Glaxo Group Limited | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors |
EP2982668A2 (en) | 2002-12-03 | 2016-02-10 | Pharmacyclics LLC | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders |
EP1667647A2 (en) * | 2003-10-01 | 2006-06-14 | Bristol-Myers Squibb Company | Monocyclic and bicyclic lactams as factor xa inhibitors |
EP1667647A4 (en) * | 2003-10-01 | 2008-10-22 | Bristol Myers Squibb Co | Monocyclic and bicyclic lactams as factor xa inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2361919A1 (en) | 2000-08-17 |
JP2002536437A (en) | 2002-10-29 |
EP1175405A1 (en) | 2002-01-30 |
EP1175405A4 (en) | 2002-05-15 |
AU756174B2 (en) | 2003-01-09 |
AU2630000A (en) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6642252B2 (en) | Acid derivatives useful as serine protease inhibitors | |
US6511977B1 (en) | Potassium channel inhibitors and method | |
JP2002536411A (en) | Lactam inhibitors of factor Xa and methods | |
US6344450B1 (en) | Lactam compounds and their use as inhibitors of serine proteases and method | |
EP0648780A1 (en) | Heterocyclic thrombin inhibitors | |
EA013017B1 (en) | Triazolopyridines as inhibitors of 11-beta-hydroxysteroid dehydrogenase type i | |
CZ282359B6 (en) | Derivatives of amidinophenylalanine and amidinopyridylalanine, process and intermediates for their preparation, their use and pharmaceutical compositions based thereon | |
RU2156763C2 (en) | Nitrogen-containing heterocyclic derivatives, pharmaceutical composition based on said and method of treatment or prophylaxis of thrombotic diseases | |
US6544981B2 (en) | Lactam inhibitors of factor Xa and method | |
AU756174B2 (en) | Lactam inhibitors of FXa and method | |
SK165398A3 (en) | New amino acid derivatives and their use as thrombin inhibitors | |
US6713467B2 (en) | Acid derivatives useful as serine protease inhibitors | |
US20040073025A1 (en) | Thrombin inhibitors | |
EA018502B1 (en) | New heterocyclic carboxamides and pharmaceutical compositions containing them | |
WO2004032834A2 (en) | Thrombin inhibitors | |
US6160134A (en) | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines | |
US5610308A (en) | Process for preparing intermediates for thrombin inhibitors | |
US5612373A (en) | Certain diacyl hydrazine derivatives | |
AU4360200A (en) | Bicyclic acyl guanidine sodium/proton exchange inhibitors and method | |
EP1340753B1 (en) | Carbamate derivatives, process for producing the same and use thereof | |
JP4660197B2 (en) | 2- (5-chlorothien-2-yl) -N-{(3S) -1-[(1S) -1-methyl-2-morpholin-4-yl-2-oxoethyl] -2-oxopyrrolidine-3- Il} ethenesulfonamide crystalline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 598484 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2361919 Country of ref document: CA Ref country code: CA Ref document number: 2361919 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 26300/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000904564 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904564 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 26300/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000904564 Country of ref document: EP |